Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents.

Tarride JE, Burke N, Von Keyserlingk C, O'Reilly D, Xie F, Goeree R.

Clinicoecon Outcomes Res. 2012;4:287-98. doi: 10.2147/CEOR.S33444.

2.

Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.

Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ.

Vaccine. 2008 Jun 2;26(23):2841-8. doi: 10.1016/j.vaccine.2008.03.046.

PMID:
18462851
3.

Vaccination of children with a live-attenuated, intranasal influenza vaccine - analysis and evaluation through a Health Technology Assessment.

Andersohn F, Bornemann R, Damm O, Frank M, Mittendorf T, Theidel U.

GMS Health Technol Assess. 2014 Oct 30;10:Doc03. doi: 10.3205/hta000119.

4.

Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.

Thommes EW, Ismaila A, Chit A, Meier G, Bauch CT.

BMC Infect Dis. 2015 Oct 27;15:465. doi: 10.1186/s12879-015-1193-4.

5.

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.

Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B; CAIV-T Asthma Study Group..

Pediatr Infect Dis J. 2006 Oct;25(10):860-9.

PMID:
17006278
6.

The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults.

Ambrose CS, Levin MJ, Belshe RB.

Influenza Other Respir Viruses. 2011 Mar;5(2):67-75. doi: 10.1111/j.1750-2659.2010.00183.x. Review.

7.

The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies.

Ambrose CS, Wu X, Knuf M, Wutzler P.

Vaccine. 2012 Jan 20;30(5):886-92. doi: 10.1016/j.vaccine.2011.11.104.

8.

Seasonal influenza vaccination for children in Thailand: a cost-effectiveness analysis.

Meeyai A, Praditsitthikorn N, Kotirum S, Kulpeng W, Putthasri W, Cooper BS, Teerawattananon Y.

PLoS Med. 2015 May 26;12(5):e1001829; discussion e1001829. doi: 10.1371/journal.pmed.1001829.

9.

A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years.

Tennis P, Toback SL, Andrews E, McQuay LJ, Ambrose CS.

Vaccine. 2011 Jul 12;29(31):4947-52. doi: 10.1016/j.vaccine.2011.04.113.

10.

Emerging data on the safety and efficacy of influenza vaccines in children.

Vesikari T.

Pediatr Infect Dis J. 2008 Nov;27(11 Suppl):S159-61. doi: 10.1097/INF.0b013e31818a545d.

PMID:
18955892
11.

Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel.

Wang Z, Tobler S, Roayaei J, Eick A.

JAMA. 2009 Mar 4;301(9):945-53. doi: 10.1001/jama.2009.265.

PMID:
19255113
12.

A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season.

Tennis P, Toback SL, Andrews EB, McQuay LJ, Ambrose CS.

Vaccine. 2012 Sep 14;30(42):6099-102. doi: 10.1016/j.vaccine.2012.07.031.

13.

Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.

Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, Wittes J.

Vaccine. 2009 Feb 11;27(7):1101-10. doi: 10.1016/j.vaccine.2008.11.093.

PMID:
19095024
14.

The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing.

Ambrose CS, Dubovsky F, Yi T, Belshe RB, Ashkenazi S.

Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2549-57.

15.

Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.

Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, Krüger H, Greiner W.

Eur J Health Econ. 2015 Jun;16(5):471-88. doi: 10.1007/s10198-014-0586-4.

17.

A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age.

Toback SL, Ambrose CS, Eaton A, Hansen J, Aukes L, Lewis N, Wu X, Baxter R.

Vaccine. 2013 Apr 3;31(14):1812-8. doi: 10.1016/j.vaccine.2013.01.055.

18.

Background paper to the recommendation for the preferential use of live-attenuated influenza vaccine in children aged 2-6 years in Germany.

Falkenhorst G, Harder T, Remschmidt C, Terhardt M, Zepp F, Ledig T, Wicker S, Keller-Stanislawski B, Mertens T.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Nov;56(11):1557-64. doi: 10.1007/s00103-013-1844-9. Erratum in: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Apr;57(4):473-4.

PMID:
24170085
19.

An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years.

Ambrose CS, Yi T, Falloon J.

Influenza Other Respir Viruses. 2011 Nov;5(6):389-97. doi: 10.1111/j.1750-2659.2011.00243.x.

20.

Influence of prior influenza vaccination on antibody and B-cell responses.

Sasaki S, He XS, Holmes TH, Dekker CL, Kemble GW, Arvin AM, Greenberg HB.

PLoS One. 2008 Aug 20;3(8):e2975. doi: 10.1371/journal.pone.0002975.

Items per page

Supplemental Content

Support Center